By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Selective immunosuppressants > Natalizumab > Natalizumab Dosage
Selective immunosuppressants
https://themeditary.com/dosage-information/natalizumab-dosage-11351.html

Natalizumab Dosage

Drug Detail:Natalizumab (Natalizumab)

Drug Class: Selective immunosuppressants

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Multiple Sclerosis

300 mg IV over 1 hour once every 4 weeks

Comments:

  • Only prescribers registered in the MS TOUCH (R) Prescribing Program may prescribe this drug for multiple sclerosis.
  • Patients should be observed during the infusion and for one hour after the infusion is complete.

Use: Multiple Sclerosis (MS): As monotherapy for the treatment of patients with relapsing forms of multiple sclerosis

Usual Adult Dose for Crohn's Disease - Maintenance

300 mg IV over 1 hour once every 4 weeks

Comments:

  • Only prescribers registered in the CD TOUCH (R) Prescribing Program may prescribe this drug for Crohn's disease.
  • This drug should not be used with concomitant immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, methotrexate) or concomitant inhibitors of TNF-alpha.
  • Aminosalicylates may be continued during treatment with this drug.
  • If the patient has not experienced therapeutic benefit by 12 weeks of induction therapy, this drug should be discontinued.
  • For patients who start this drug while on chronic oral corticosteroids, steroid tapering should commence as soon as a therapeutic benefit of this drug has occurred; if the patient cannot be tapered off of oral corticosteroids within 6 months of starting this drug, then this drug should be discontinued.
  • Other than the initial 6 month taper, prescribers should consider discontinuing this drug for patients who require additional steroid use that exceeds 3 months in a calendar year to control their Crohn's disease.
  • Patients should be observed during the infusion and for one hour after the infusion is complete.

Use: Crohn's Disease (CD): For inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate conventional CD therapies and inhibitors of TNF-alpha

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US REMS: The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for natalizumab (R). It includes a medication guide, elements to assure safe use, and implementation system. For additional information: www.fda.gov/REMS
RESTRICTED DISTRIBUTION PROGRAM:

  • Because of the risk of PML, this drug is available only through a special restricted distribution program called the TOUCH (R) Prescribing Program.
  • Only prescribers, infusion centers, and pharmacies associated with infusion centers registered with the program are able to prescribe, distribute, or infuse the product.
  • For physicians and patients, the TOUCH (R) Prescribing Program has 2 components:
1) MS TOUCH (R) for patients with multiple sclerosis
2) CD TOUCH (R) (for patients with Crohn's disease)
Requirements of the TOUCH (R) Prescribing Program include the following:
Prescribers must be certified and comply with the following:
  • Review the TOUCH (R) Prescribing Program prescriber educational materials, including the full prescribing information.
  • Educate patients on the benefits and risks of treatment with this drug, ensure that patients receive the Medication Guide, and encourage them to ask questions.
  • Review, complete, and sign the Patient-Prescriber Enrollment Form.
  • Evaluate patients 3 months after the first infusion, 6 months after the first infusion, every 6 months thereafter, and for at least 6 months after discontinuing therapy.
  • Determine every 6 months whether patients should continue on treatment and, if so, authorize treatment for another 6 months.
  • Submit to Biogen Idec the "TYSABRI (R) Patient Status Report and Reauthorization Questionnaire" 6 months after initiating treatment and every 6 months thereafter.
  • Complete an "Initial Discontinuation Questionnaire" when therapy is discontinued, and a "6-Month Discontinuation Questionnaire" following discontinuation of therapy.
  • Report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen Idec at 1-800-456-2255 as soon as possible.
  • Patients must be enrolled in the TOUCH (R) Prescribing Program, read the Medication Guide, understand the risks associated with this drug, and complete and sign the Patient-Prescriber Enrollment Form.
  • Pharmacies and infusion centers must be specially certified to dispense or infuse this drug.

US BOXED WARNINGS:
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY:
  • This drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability.
  • Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies. These factors should be considered in the context of expected benefit when initiating and continuing treatment.
  • Healthcare professionals should monitor patients on this drug for any new sign or symptom that may be suggestive of PML.
  • This drug should be withheld immediately at the first sign or symptom suggestive of PML.
  • For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.
  • Because of the risk of PML, this drug is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Therapy with this drug should be initiated and supervised by neurologists, in centers with timely access to MRI.
  • This drug should be administered within 8 hours of preparation.

Storage advice:
  • Consult the manufacturer product information.

Reconstitution/preparation techniques:
  • Consult the manufacturer product information.

General:
  • This drug should not be administered as an IV push or bolus.
  • In CD, discontinue in patients that have not experienced therapeutic benefit by 12 weeks of induction therapy, and in patients that cannot discontinue chronic concomitant steroids within six months of starting therapy.

Monitoring:
  • Patients should be observed during the infusion and for one hour after the infusion is complete for adverse reactions.

Frequently asked questions

  • How long can you take Tysabri for?
  • Does Tysabri suppress the immune system?
  • Is Tysabri a form of chemotherapy?
  • Does Tysabri cause cancer?
  • How to prevent hair loss from Tysabri (natalizumab)?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by